CN103420982A - Dabigatran derivative, and preparation method and application thereof - Google Patents

Dabigatran derivative, and preparation method and application thereof Download PDF

Info

Publication number
CN103420982A
CN103420982A CN2012101642641A CN201210164264A CN103420982A CN 103420982 A CN103420982 A CN 103420982A CN 2012101642641 A CN2012101642641 A CN 2012101642641A CN 201210164264 A CN201210164264 A CN 201210164264A CN 103420982 A CN103420982 A CN 103420982A
Authority
CN
China
Prior art keywords
dabigatran
formula
ester derivative
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012101642641A
Other languages
Chinese (zh)
Other versions
CN103420982B (en
Inventor
孔维苓
蔡志强
徐为人
周植星
付晓丽
汤立达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to CN201210164264.1A priority Critical patent/CN103420982B/en
Publication of CN103420982A publication Critical patent/CN103420982A/en
Application granted granted Critical
Publication of CN103420982B publication Critical patent/CN103420982B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention relates to a preparation method of a benzimidazole derivative shown as a general formula I, wherein R1, R2 and R3 are defined as in the specification. The invention relates to a Dabigatran derivative shown as the general formula I and non-toxic pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing these compounds as active components, and application of the compounds and the pharmaceutical composition as thrombin inhibitors.

Description

Dabigatran ester derivative and its production and use
Technical field
The present invention relates to the synthetic field of medicine, be specifically related to ester derivative of dabigatran and preparation method thereof, the pharmaceutical composition that contains these derivatives and described compound and pharmaceutical composition are as the purposes of thrombin inhibitors.
Background technology
Dabigatran etcxilate (Dabigatran) is the novel anticoagulation medicine with various features of German Boehringer Ingelheim company exploitation.In April, 2008, at first, in Germany and Britain's listing, commodity are called Pradaxa, for preventing and treating Acute Venous thrombus (VTE).This is the oral new drug of the anticoagulation of first listing over 50 years after warfarin, is another milestone in anticoagulation therapy field and potential lethality thrombus prevention field.U.S. food and Drug Administration approval Pradaxa capsule on October 19th, 2010 (dabigatran etcxilate) is preventing apoplectic and blood coagulation in rhythm abnormality (atrial fibrillation) patient is arranged.
Zymoplasm is extracellular Insulin-Like serine protease, has vital role in coagulation process, and on the one hand, it can make the Fibrinogen cracking become scleroproein, and the latter participates in forming the hard clot suppository matrix; On the other hand, it can activate and assemble by induced platelet, and then causes the reaction of series of secondary coagulation cascade.Dabigatran etcxilate is prodrug, is converted in vivo activated dabigatran, and dabigatran is brought into play the anticoagulation effect by direct Trombin inhibiting.Dabigatran etcxilate is a kind of novel synthetic direct thrombin inhibitor, is for oral prodrug, belongs to the thrombin inhibitors of non-peptide class.Oral after stomach and intestine absorb, be converted in vivo the dabigatran with direct anticoagulant active.Medicine is incorporated into the scleroproein specific combination site of zymoplasm, stops Fibrinogen to be cracked into scleroproein, thereby has blocked final step and the thrombosis of blood coagulation waterfall network.
But the oral administration biaavailability of dabigatran etcxilate lower (<6.5%), therefore remain further to be improved.
Summary of the invention
The present invention relates to ester derivative and non-toxicity pharmacy acceptable salt thereof by the dabigatran shown in the structural formula I, and contain the pharmaceutical composition of these compounds as activeconstituents, and described compound and pharmaceutical composition are as the purposes of thrombin inhibitors.
Therefore first aspect of the present invention provides ester derivative and the pharmacologically acceptable salt thereof of the dabigatran of formula I representative:
Figure BDA0000167674122
Wherein,
R 1Represent H or C 1-C 5Alkyl; R 2Represent H or C 1-C 3Alkyl; R 3Represent C 1-C 6Alkyl or the alkyl of replacement.
Preferably, the invention provides ester derivative or its pharmacologically acceptable salt, the wherein R of the dabigatran of formula I representative 1Represent H or C 1-C 2Alkyl, R 2Represent H or CH 3, R 3Represent C 1-C 6Alkyl.
More preferably, the invention provides the ester derivative of dabigatran of formula I representative or the compound that its pharmacologically acceptable salt is selected from following structural formula representative:
Figure BDA0000167674123
Each substituting group of objectives compound is defined as follows respectively:
I 1: R 1For-CH 3, R 2For-H, R 3For-CH 3
I 2: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 3
I 3: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 3
I 4: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 3
I 5: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 2CH 3
I 6: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 2CH 2CH 3
I 7: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 3
I 8: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 3
I 9: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 3
I 10: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 3
I 11: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 2CH 3
I 12: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 2CH 2CH 3
I 13: R 1For-CH 3, R 2For-CH 3, R 3For-CH 3
I 14: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 3
I 15: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 3
I 16: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 3
I 17: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 2CH 3
I 18: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 2CH 2CH 3
I 19: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 3
I 20: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 3
I 21: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 3
I 22: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 3
I 23: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 2CH 3
I 24: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 2CH 2CH 3.
Second aspect of the present invention relates to pharmaceutical composition, and it comprises ester derivative or its pharmacologically acceptable salt of the dabigatran of at least one formula I representative, and one or more pharmaceutically acceptable carrier or vehicle.
Second aspect of the present invention relates to ester derivative and the non-toxicity pharmacy acceptable salt thereof of the dabigatran shown in the formula I, and the ester derivative that comprises the dabigatran shown in the formula I and non-toxicity pharmacy acceptable salt thereof as the pharmaceutical composition of activeconstituents as anticoagulant purposes.
The compound of formula I representative can form pharmaceutical salts with mineral acid, for example vitriol, phosphoric acid salt, hydrochloride, hydrobromate; Also can form pharmaceutical salts with organic acid, such as acetate, oxalate, Citrate trianion, succinate, gluconate, tartrate, tosilate, benzene sulfonate, mesylate, benzoate, lactic acid salt, maleate etc.Selecting and preparing suitable salt is technology as well known to those skilled in the art.
The compounds of this invention or its pharmacologically acceptable salt can be separately or with the form administration of pharmaceutical composition.Pharmaceutical composition of the present invention can be made into various suitable dosage forms according to route of administration.Use acceptable carrier on one or more physiology, comprise vehicle and auxiliary agent, they are conducive to active compound is processed into to the preparation that can pharmaceutically use.Suitable dosage form depends on selected route of administration, can be prepared according to general knowledge well known in the art.
Route of administration can be oral, non-enteron aisle or topical, preferred oral and injection form administration.Can comprise capsule and tablet etc. by oral pharmaceutical preparation.The compounds of this invention also can be prepared for administered parenterally or transdermal administration or mucosal, or adopts the mode administration of suppository or implants.It will be understood by those skilled in the art that the compounds of this invention can adopt suitable drug delivery system (DDS) to obtain more favourable effect.
Embodiment
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
At first reference (Hauel NH, Nar H, Priepke H, et al.Structure-Based Design of Novel Potent NopePtide Thrombin Inhibitors. J.Med. Chem.2002; 45:1757-1766) the ester derivative of the dabigatran shown in the synthetic dabigatran etcxilate of method and formula I:
R 1=H ,-CH 3,-CH 2CH 3R 2=H, CH 3, R 3=C 1-C 6Alkyl or the alkyl of replacement.
Take compound 1 as starting raw material, through amidation, condensation, obtain intermediate 2; Intermediate 2 is reacted with sodium hydroxide and reacts with chloroparaffin and obtain intermediate 3, and intermediate 3 reacts and obtains intermediate 4 with acidic alcohol and ammonia ethanolic soln, and intermediate 4 reacts from the Acibenzolar of different replacements the ester derivative (I that obtains dabigatran 1-32)
Embodiment 1 (E)-methyl 3-(2-((4-(N'-(methoxycarbonyl) amidino) benzene oxygen) methyl)-1-methyl-N-(pyridine-2-yl)-1H-benzoglyoxaline-5-formamido-) methyl propionate (I 1) preparation
1) ethyl 3-(2-((4-cyano-benzene oxygen) methyl)-1-methyl-N-(pyridine-2-yl) amino)-1H-benzoglyoxaline-5-formamido-) ethyl propionate (2A) is synthetic
2-(4-cyano group-phenoxy group)-acetic acid (1.6 g, 0.0l mo1), EDC1 (1.9 g, 0.01 mo1), I-hydroxybenzotriazole (1.3 5 g, 0.01 mo1) is dissolved in THF (35 m1) and DMF (5 m1) mixed solution.Stir 35 min in ice-water bath, rise to room temperature, slowly drip THF (15m1) solution of 1 (3.1 g, 0.009 mo1).Finish and stir 6 h.Boil off solvent, add methylene dichloride (30 m1), with saturated brine (5 mL x 3), wash, after anhydrous sodium sulfate drying, filter, filtrate is concentrated into dry, ice acetic acid in residuum (45 m1), reflux 2 h, be evaporated to dry, add strong aqua (15 m1) in residuum, stirring at room 30 min boil off solvent, add methylene dichloride (25 m1) in residuum, through saturated brine (5 mL x 3), wash, after anhydrous sodium sulfate drying, filter, filtrate is concentrated into dry, and residuum, through the column chromatography purifying, obtains amorphous yellow solid 3.1 g.
2) methyl 3-(2-((4-cyano-benzene oxygen) methyl)-1-methyl-N-(pyridine-2-yl)-1H-benzoglyoxaline-5-formamido-) methyl propionate (3Aa) is synthetic
5.0 g intermediate 2A are dissolved in 200mL ethanol, add the sodium hydroxide solution 10mL of 1N, under room temperature, stirring reaction is complete to hydrolysis, evaporate to dryness, dissolve with 20mLDMF, adds the 1.76g methyl iodide, stirring at room 24 hours, concentrated, the post separation obtains 4.0g target intermediate.
3) methyl 3-(2-((4-amidino phenoxy group) methyl)-1-methyl-N-(pyridine-2-yl)-1H-benzoglyoxaline-5-formamido-) methyl propionate (4 Aa) is synthetic
4.0g intermediate 3Aa is dissolved in 100 mL ethanol, be cooled to 0 ℃, pass into dry hydrogen chloride gas to saturated, stirred overnight at room temperature, add 100 mL ethanol in the solvent evaporated resistates, slowly add the ammonia ethanolic soln under cooling conditions, and at room temperature stir 12 hours, solvent evaporated, column chromatography purification obtains white solid 2.5g.
4) (E)-methyl 3-(2-((4-(N'-(methoxycarbonyl) amidino) benzene oxygen) methyl)-1-methyl-N-(pyridine-2-yl)-1H-benzoglyoxaline-5-formamido-) methyl propionate (I 1) synthetic
Upper step product (4 Aa) is dissolved in tetrahydrofuran (THF) (50 mL), adds methyl-chloroformate (0.534 g) and DIEA (3 mL), stirred overnight at room temperature, evaporate to dryness, column chromatography purification obtains white target product 1.8g. 1H?NMR(DMAO-d 6,400?MHz)δ:?2.69(d,?J=7.2Hz,?2H,?CH 2),?3.42(s,?3H,?CH 3),?3.59(d,?J=7.2?Hz,?2H,?CH 2),?3.68(s,?3H,?CH 3),?3.72(s,?3H,?CH 3),?5.33(s,?2H,?CH 2),?6.62(m,?1H,?ArH),?6.7(d,?J=8,?1H,?ArH),?7.06~7.46(m,?4H,?ArH),?7.55(m,?1H,?ArH),?7.64(d,?J=7.5,?1H,?ArH),?7.72(m,?1H,?ArH),?8.07(d,?J=7.5,?1H,?ArH),?8.11(s,?1H,?ArH),?8.50-9.30(br?s,?2H,?NH 2),?ESI-MS:?m/z?545?[M+H] +。
Embodiment 2-24
With reference to the operation of embodiment 1, difference is to select different phenoxy acetic acids, and different carboxylicesterss reacts from different Acibenzolar side chains, obtains the compound of following formula I.
Figure BDA0000167674127
Figure BDA0000167674128
The mensuration of embodiment 25 anticoagulating active evaluation-activated partial thromboplastin times (aPPT)
By the kunming mice of quality 18-20g, random packet, 10 every group, overnight fasting.Dabigatran etcxilate and target compound to be measured are suspended or be dissolved in the aqueous solution of 1% Xylo-Mucine, be made into the concentration of 1mg/mL, dosage (amounting to into dabigatran calculates) gastric infusion by 10mg/Kg, pass through heart puncturing extracting blood after half an hour, add 4% matrimony vine acid sodium solution to 0.4% final concentration anti-freezing, centrifugal 5 minutes of 12000r/min, get blood plasma 0.1mL, add aPPT reagent 0.1mL, 37 ℃ of pre-temperature are after 3 minutes, the calcium chloride solution 0.1mL that adds 37 ℃ of pre-temperature, by platelet aggregation thrombin analysis-e/or determining setting time, be the aPPT value.The results are shown in Table 1.
The measurement result of table 1 activated partial thromboplastin time (aPPT)
Compound aPPT(sec)
Physiological saline 21.3±4.4
Dabigatran etcxilate 75.4±2.0
Ⅰ 3 112.4±3.9
Ⅰ 4 105.9±3.1
Ⅰ 5 165.2±4.7
Ⅰ 10 147.6±3.6
Ⅰ 12 135.9±3.0
Ⅰ 13 77.1±2.8
Ⅰ 14 68.5±3.7
Ⅰ 16 102.4±3.0
Ⅰ 17 95.9±3.2
Ⅰ 18 145.2±4.5
Ⅰ 22 127.6±3.3
Ⅰ 23 80.9±3.6
Ⅰ 24 165.1±2.9

Claims (7)

1. the ester derivative or its pharmacy acceptable salt that there is the dabigatran of formula I structure:
Figure FDA0000167674111
Wherein,
R 1For H or C 1-C 5Alkyl; R 2For H or C 1-C 3Alkyl; R 3For C 1-C 6Alkyl or the alkyl of replacement.
2. ester derivative or its pharmacy acceptable salt with dabigatran of formula I structure according to claim 1:
Wherein,
R 1For H or C 1-C 2Alkyl; R 2For H or CH 3R 3For C 1-C 6Alkyl.
3. according to described ester derivative or its pharmacy acceptable salt with dabigatran of formula I structure of claim 1-2 any one, be selected from the compound of following structural formula representative:
Wherein, R 1, R 2And R 3Be defined as follows respectively:
I 1: R 1For-CH 3, R 2For-H, R 3For-CH 3
I 2: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 3
I 3: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 3
I 4: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 3
I 5: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 2CH 3
I 6: R 1For-CH 3, R 2For-H, R 3For-CH 2CH 2CH 2CH 2CH 2CH 3
I 7: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 3
I 8: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 3
I 9: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 3
I 10: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 3
I 11: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 2CH 3
I 12: R 1For-CH 2CH 3, R 2For-H, R 3For R 3-CH 2CH 2CH 2CH 2CH 2CH 3
I 13: R 1For-CH 3, R 2For-CH 3, R 3For-CH 3
I 14: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 3
I 15: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 3
I 16: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 3
I 17: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 2CH 3
I 18: R 1For-CH 3, R 2For-CH 3, R 3For-CH 2CH 2CH 2CH 2CH 2CH 3
I 19: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 3
I 20: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 3
I 21: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 3
I 22: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 3
I 23: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 2CH 3
I 24: R 1For-CH 2CH 3, R 2For-CH 3, R 3For R 3-CH 2CH 2CH 2CH 2CH 2CH 3.
4. according to described ester derivative or its pharmacy acceptable salt with dabigatran of formula I structure of claim 1-3 any one, the salt that the ester derivative of the dabigatran that described salt is formula I structure becomes with organic acid or mineral acid.
5. ester derivative or its pharmacy acceptable salt with dabigatran of formula I structure according to claim 4, described salt can be vitriol, phosphoric acid salt, hydrochloride, hydrobromate, acetate, oxalate, Citrate trianion, succinate, gluconate, tartrate, tosilate, benzene sulfonate, mesylate, benzoate, lactic acid salt, maleate.
6. a pharmaceutical composition, it is characterized in that, comprise at least one ester derivative or its pharmacy acceptable salt with dabigatran of formula I structure as described as claim 1-3 any one, and one or more pharmaceutically acceptable carrier or vehicle.
7. according to described ester derivative or the purposes of its pharmacy acceptable salt in preparing thrombin inhibitors with dabigatran of formula I structure of claim 1-3 any one.
CN201210164264.1A 2012-05-24 2012-05-24 Dabigatran derivative, and preparation method and application thereof Expired - Fee Related CN103420982B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210164264.1A CN103420982B (en) 2012-05-24 2012-05-24 Dabigatran derivative, and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210164264.1A CN103420982B (en) 2012-05-24 2012-05-24 Dabigatran derivative, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN103420982A true CN103420982A (en) 2013-12-04
CN103420982B CN103420982B (en) 2015-07-08

Family

ID=49646406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210164264.1A Expired - Fee Related CN103420982B (en) 2012-05-24 2012-05-24 Dabigatran derivative, and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN103420982B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554370A (en) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 Dabigatran derivant containing phosphate ester and its production and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101980697A (en) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 Process for preparing orally administered dabigatran formulations
WO2011061080A1 (en) * 2009-11-18 2011-05-26 Boehringer Ingelheim International Gmbh Method for producing dabigatran etexilate
CN102123707A (en) * 2008-08-19 2011-07-13 贝林格尔.英格海姆国际有限公司 Dabigatran for percutaneous interventional cardiac catheterisation
CN102391250A (en) * 2011-08-29 2012-03-28 石药集团欧意药业有限公司 Dabigatran compound and preparation method and medicinal composition thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101980697A (en) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 Process for preparing orally administered dabigatran formulations
CN102123707A (en) * 2008-08-19 2011-07-13 贝林格尔.英格海姆国际有限公司 Dabigatran for percutaneous interventional cardiac catheterisation
WO2011061080A1 (en) * 2009-11-18 2011-05-26 Boehringer Ingelheim International Gmbh Method for producing dabigatran etexilate
CN102391250A (en) * 2011-08-29 2012-03-28 石药集团欧意药业有限公司 Dabigatran compound and preparation method and medicinal composition thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554370A (en) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 Dabigatran derivant containing phosphate ester and its production and use

Also Published As

Publication number Publication date
CN103420982B (en) 2015-07-08

Similar Documents

Publication Publication Date Title
CN102875529B (en) Dabigatran derivatives and preparation method thereof
CN102050815B (en) Dabigatran ester derivatives as prodrug
CN102050814B (en) Ester derivatives of dabigatran
CN106432218B (en) Razaxaban impurity and its preparation method and application
US6642224B1 (en) Diazepan derivatives or salts thereof
WO2016007046A1 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
WO2024040768A1 (en) 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
CN106831556A (en) Sulfamide compound and preparation method thereof and the purposes as lithate transporter inhibitors class medicine
CN109503548B (en) Butylphthalide derivative and preparation method and application thereof
CN103420985B (en) As the dabigatran ester derivative and its production and use of prodrug
CN103420980A (en) Dabigatran derivatives
CN103420984B (en) Dabigatran derivative used as prodrug, and preparation method and application thereof
CN103420983B (en) Dabigatran derivative, and preparation method and application thereof
CN103420982B (en) Dabigatran derivative, and preparation method and application thereof
CN105646531B (en) Dabigatran cyclic derivatives and its production and use
CN109293660B (en) rutaecarpine-NO donor conjugate and application thereof
CN103420994B (en) As the dabigatran ester derivative and its production and use of prodrug
CN102993175B (en) Dabigatran derivatives, and preparation method and application thereof
SK281017B6 (en) 3,4-dihydroisoquinoline derivates, method of their preparation, pharmaceuticals them containing and their use
CN102250099B (en) Non-peptide thrombin inhibitors as well as preparation method and medical application thereof
CN103554087A (en) Dabigatran derivative, as well as preparation method and antithrombus application thereof
CZ2003835A3 (en) Method for efficient preparation of Xa factor inhibitor
CN102993174A (en) Dabigatran etexilate derivative as a prodrug
CN104628714A (en) Ester derivative of dabigatran as well as preparation method and application thereof
CN107141268B (en) A kind of Paeonol phenylacetic acid compound, preparation method and medical usage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150708

Termination date: 20210524

CF01 Termination of patent right due to non-payment of annual fee